First Nigerian manufacturer obtains WHO prequalification for key malaria prevention drug

Swipha, a leading Nigerian pharmaceutical manufacturer, has achieved World Health Organization (WHO) prequalification for their sulfadoxine-pyrimethamine (SP) 500/25mg tablet, a crucial medication for preventing malaria in pregnant women. This milestone follows extensive research, product formulation, and a bioequivalence study to ensure efficacy and safety. Supported by Medicines for Malaria Venture (MMV) and funded by Unitaid, this accomplishment is part of a global initiative to ensure quality and sustainable supplies of malaria medicines. Read the full article in the attachment.